Evidence map›Paper›PMID 32445173›Full record

ArticleEndocrine pathology2020

Histopathologic Features and Clinical Outcome of Anaplastic Thyroid Carcinoma with a Minor Anaplastic Component.

Kristine S Wong, Jochen H Lorch, Erik K Alexander, Ellen Marqusee, Nancy L Cho, Matthew A Nehs, Gerard M Doherty, Justine A Barletta

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kristine S WongDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jochen H LorchDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Erik K AlexanderDivision of Endocrinology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ellen MarquseeDivision of Endocrinology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Nancy L ChoDepartment of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Matthew A NehsDepartment of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Gerard M DohertyDepartment of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Justine A BarlettaDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. jbarletta@bwh.harvard.edu.
Brigham and Women's Hospital · USHarvard University · USDana-Farber Cancer Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although prior studies have reported that patients with anaplastic thyroid carcinoma (ATC) with a focal anaplastic component may have a prolonged survival compared to other ATC patients, the outcome data are limited. We evaluated a cohort of ATC resected between 2003 and 2018. Tumor slides were reviewed to confirm the diagnosis and to identify cases with a minor ATC component (defined as comprising < 10% of the tumor). We evaluated the clinical outcome of these patients compared to that of all other cohort patients (characterized as having conventional ATC). Our cohort was composed of 24 cases of ATC that underwent resection, including 8 (33%) with a minor ATC component. Tumors with a minor ATC component were predominantly associated with papillary thyroid carcinoma. For patients with tumors with a minor ATC component, the 1-year and 2-year survival rates and median survival for patients who died of disease were 88%, 43%, and 17 months (range 6-73 months), respectively. In comparison, for patients with conventional ATC, the 1-year and 2-year survival rates and median survival for patients who died of disease were 56%, 44%, and 7 months (range 2-26 months), respectively. There was no difference in 1- and 2-year survival or overall survival by Kaplan-Meier analysis for patients with tumors with a minor ATC component and those with conventional ATC. In conclusion, the difference in overall survival between ATC groups in our cohort was not significant; however, this could be due to the small cohort size or due to characteristics of our group with a minor ATC component; that is, no tumors in this group were limited to the thyroid (stage IVA), resectability with negative margins was infrequent, and 38% of this group had distant metastases at diagnosis (stage IVC).

Indexed as

AgedAged, 80 and overCohort StudiesFemaleHumansMaleMargins of ExcisionMiddle AgedNeoplasm MetastasisNeoplasm StagingPhenotypePrognosisRetrospective StudiesThyroid Carcinoma, AnaplasticThyroidectomyThyroid NeoplasmsAnaplastic thyroid carcinoma

Identifiers

PMID32445173
OpenAlexW3027021249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.